uniQure NV QURE 深 滬
等待開盤 09-24 09:30:00 美东时间
42.76
-2.520
-5.57%
華盛通- 最 高45.41
- 今 開45.17
- 成交量 117.29万股
- 最 低 42.625
- 昨 收 45.28
- 總市值 29.66亿
- 52周最高 71.50
- 市盈率 靜 --
- 換手率 1.69%
- 52周最低 8.73
- 委 比 0.00%
- 總股本 6936.64万
- 歷史最高 82.49
- 量 比 0.93
- 振 幅 6.15%
- 歷史最低 3.73
- 每 手 1
- 風險率 14.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多William Blair Reinstates Outperform on uniQure
William Blair analyst Sami Corwin reinstates uniQure (NASDAQ:QURE) with a Outperform.
09-03 03:36
uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the accelerated approval of...
09-02 19:10
uniQure Charts Accelerated Path With AMT‑130
uniQure N.V. (($QURE)) has held its Q2 earnings call. Read on for the main high...
08-17 08:30
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Barclays Maintains Overweight on uniQure, Lowers Price Target to $60
Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the price target from $65 to $60.
07-30 19:55
财报速睇 | uniQure NV 2026财年Q2营收0.06亿美元，同比增长11.0%；归母净利润亏损0.81亿美元，同比亏损扩大114.9%
华盛资讯7月29日讯，uniQure NV公布2026财年Q2业绩，公司Q2营收0.06亿美元，同比增长11.0%，归母净利润亏损0.81亿美元，同比亏损扩大114.9%。
07-29 19:35
财报速睇 | uniQure NV 2026财年Q2营收0.06亿美元，同比增长11.0%；归母净利润亏损0.81亿美元，同比亏损扩大114.9%
华盛资讯7月29日讯，uniQure NV公布2026财年Q2业绩，公司Q2营收0.06亿美元，同比增长11.0%，归母净利润亏损0.81亿美元，同比亏损扩大114.9%。
07-29 19:19
uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate
uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.82) by 48.78 percent. This is a 76.81 percent decrease over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $5.800 million which...
07-29 19:07
uniQure to Announce Second Quarter 2026 Financial Results
uniQure N.V., a gene therapy company, will report its second quarter 2026 financial results on July 29, 2026, followed by a conference call at 8:30 a.m. ET. The event will be webcast on uniQure’s website, with a replay available for 90 days. Analysts can join the call via dial-in numbers provided. The company specializes in developing gene therapies for severe diseases, including hemophilia B, Huntington's disease, and Fabry disease.
07-22 11:05
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
